Molecular Response to Aromatase Inhibitor Treatment in Primary Breast Cancer
Author Information
Author(s): Mackay Alan, Urruticoechea Ander, Dixon J Michael, Dexter Tim, Fenwick Kerry, Ashworth Alan, Drury Suzanne, Larionov Alexey, Young Oliver, White Sharon, Miller William R, Evans Dean B, Dowsett Mitch
Primary Institution: The Institute of Cancer Research
Hypothesis
What are the molecular effects of aromatase inhibitors on human breast carcinomas in vivo?
Conclusion
Aromatase inhibitor treatment leads to significant changes in gene expression in primary breast tumors, which may help identify factors influencing treatment response.
Supporting Evidence
- The study identified 1,395 genes that were upregulated and 1,264 genes that were downregulated by AI treatment.
- A significant correlation was found between the Global Index of Dependence on Estrogen (GIDE) and changes in the proliferation marker Ki67.
- No significant differences were observed between the effects of letrozole and anastrozole.
Takeaway
This study looked at how two drugs that lower estrogen levels affect breast cancer cells, finding that they change many genes in the tumors.
Methodology
Patients were randomly assigned to receive either anastrozole or letrozole for 2 weeks before surgery, with gene expression analyzed from biopsies.
Potential Biases
Potential biases may arise from the selection of patients and the short duration of treatment.
Limitations
The study had a small sample size, which may limit the generalizability of the findings.
Participant Demographics
Postmenopausal women with primary estrogen receptor positive breast cancer.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website